Enzyme replacement in Fabry disease: Pharmacokinetics and pharmacodynamics of agalsidase alfa in children and adolescents

Journal of Clinical Pharmacology

Volumn 47, Issue 10, 2007, Pages 1222-1230

  Ries, Markus ^a,e   Clarke, Joe T ^b   Whybra, Catharina ^c   Mehta, Atul ^d   Loveday, Kenneth S ^e,f   Brady, Roscoe O ^a   Beck, Michael ^c   Schiffmann, Raphael ^a,g  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e SHIRE   (United States)

^f Altus Pharmaceuticals Inc   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Enzyme replacement therapy; Fabry disease; Lysosomal disorders

Indexed keywords

AGALSIDASE ALFA; GLOBOTRIAOSYLCERAMIDE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; GROUPS BY AGE; HUMAN; MALE; MULTICENTER STUDY; OPEN STUDY; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ALPHA-GALACTOSIDASE; AREA UNDER CURVE; CHILD; DRUG ADMINISTRATION SCHEDULE; FABRY DISEASE; FEMALE; HALF-LIFE; HUMANS; IMMUNOGLOBULIN G; INFUSIONS, INTRAVENOUS; ISOENZYMES; MALE; MIDDLE AGED; SEX FACTORS; TREATMENT OUTCOME; TRIHEXOSYLCERAMIDES;

EID: 34648833446     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007305299     Document Type: Article

References (32)

1. Brady RO, Gal AE, Bradley RM, Martensson E., Warshaw AL, Laster L. Enzymatic defect in Fabry's disease: ceramidetrihexosidase deficiency. N Engl J Med. 1967 ; 276: 1163-1167.
2. Gadoth N., Sandbank U. Involvement of dorsal root ganglia in Fabry's disease. J Med Genetics. 1983 ; 20: 309-312.
3. Alroy J., Sabnis S., Kopp JB Renal pathology in Fabry disease. J Am Soc Nephrol. 2002 ; 13 (suppl 2). S134 - S138.
4. Sessa A., Toson A., Nebuloni M., et al. Renal ultrastructural findings in Anderson-Fabry disease. J Nephrol. 2002 ; 15: 109-112.
5. MacDermot KD, Holmes A., Miners AH Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genetics. 2001 ; 38: 750-760.
6. Branton MH, Schiffmann R., Sabnis SG, et al. Natural history of Fabry renal disease: influence of a-galactosidase A activity and genetic mutations on clinical course. Medicine. 2002 ; 81: 122-138.
7. Mehta A., Ricci R., Widmer U., et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004 ; 34: 236-242.
8. Ries M., Ramaswami U., Parini R., et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr. 2003 ; 162: 767-772.
9. Ries M., Gupta S., Moore DF, et al. Pediatric Fabry disease. Pediatrics. 2005 ; 115: e344 - e355.
10. MacDermot KD, Holmes A., Miners AH Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genetics. 2001 ; 38: 769-775.
11. Whybra C., Kampmann C., Willers I., et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherited Metab Dis. 2001 ; 24: 715-724.
12. Whybra C., Kampmann C., Krummenauer F., et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genetics. 2004 ; 65: 299-307.
13. Eng CM, Guffon N., Wilcox WR, et al. Safety and efficacy of recombinant human a-galactosidase A replacement therapy in Fabry's disease. N Engl J Med. 2001 ; 345: 9-16.
14. Schiffmann R., Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001 ; 285: 2743-2749.
15. Schiffmann R., Floeter MK, Dambrosia JM, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve. 2003 ; 28: 703-710.
16. Weidemann F., Breunig F., Beer M., et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation. 2003 ; 108: 1299-1301.
17. Baehner F., Kampmann C., Whybra C., Miebach E., Wiethoff CM, Beck M. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherited Metab Dis. 2003 ; 26: 617-627.
18. Jardim LB, Aesse F., Vedolin LM, et al. White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up. Arquivos de Neuro-psiquiatria. 2006 ; 64: 711-717.
19. Schiffmann R., Ries M., Timmons M., Flaherty JT, Brady RO Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplantation. 2006 ; 21: 345-354.
20. Wilcox WR, Banikazemi M., Guffon N., et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genetics. 2004 ; 75: 65-74.
21. Ries M., Clarke JT, Whybra C., et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics. 2006 ; 118: 924-932.
22. Hajioff D., Enever Y., Quiney R., Zuckerman J., Mackermot K., Mehta A. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. J Inherited Metab Dis. 2003 ; 26: 787-794.
23. Bishop DF, Desnick RJ Affinity purification of a-galactosidase A from human spleen, placenta, and plasma with elimination of pyrogen contamination: properties of the purified splenic enzyme compared to other forms. J Biol Chem. 1981 ; 256: 1307-1316.
24. Schiffmann R., Murray GJ, Treco D., et al. Infusion of a-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA. 2000 ; 97: 365-370.
25. Lee K., Jin X., Zhang K., et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology. 2003 ; 13: 305-313.
26. Linthorst GE, Vedder AC, Aerts JM, Hollak CE Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clinica Chimica Acta. 2005 ; 353: 201-203.
27. Kornfeld S. Structure and function of the mannose 6-phosphate/ insulinlike growth factor II receptors. Annu Rev Biochem. 1992 ; 61: 307-330.
28. Hille-Rehfeld A. Mannose 6-phosphate receptors in sorting and transport of lysosomal enzymes. Biochimica et Biophysica Acta. 1995 ; 1241: 177-194.
29. Brady RO, Tallman JF, Johnson WG, et al. Replacement therapy for inherited enzyme deficiency: use of purified ceramidetrihexosidase in Fabry's disease. N Engl J Med. 1973 ; 289: 9-14.
30. Crawley AC, Brooks DA, Muller VJ, et al. Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. J Clin Invest. 1996 ; 97: 1864-1873.
31. Urata K., Kawasaki S., Matsunami H., et al. Calculation of child and adult standard liver volume for liver transplantation. Hepatology. 1995 ; 21: 1317-1321.
32. Silver HK, Kempe CH, Bruyn HB Handbook of Pediatrics. Los Altos, CA: Lange Medical; 1980: 79-98.